美洛昔康增加EGFR表达改善饮食诱导肥胖小鼠肝切除后生存
该研究在瘦小鼠和饮食诱导肥胖小鼠中行70%或80%肝切除,发现肥胖小鼠肝脏EGFR表达降低。通过数据库筛选发现美洛昔康可诱导EGFR表达,美洛昔康预处理改善肥胖小鼠肝脂肪变性、加速肝细胞有丝分裂和肝质量恢复,并显著提高80%肝切除后生存率。
要点
- 肥胖小鼠肝脏EGFR表达降低,是脂肪肝的常见特征。
- 美洛昔康预处理增加肥胖小鼠肝细胞EGFR蛋白表达并改善肝脂肪变性。
- 美洛昔康预处理加速肥胖小鼠肝切除后肝再生并提高80%肝切除后生存。
核心结论
- 低EGFR表达是脂肪肝疾病的共同特征,美洛昔康可恢复脂肪变性肝细胞的EGFR表达。
- 美洛昔康预处理可能用于改善脂肪肝切除或脂肪变性供肝移植后的结局。
研究设计与样本
- 研究使用瘦小鼠(20%热量来自脂肪)和饮食诱导肥胖小鼠(60%热量来自脂肪),分别行70%或80%肝切除。
- 通过BaseSpace Correlation Engine对已存基因芯片数据筛选可增加肝脏EGFR的药物。
主要发现
- 美洛昔康被鉴定为跨物种诱导EGFR表达的药剂。
- 美洛昔康在宏观和组织学上改善饮食诱导肥胖小鼠的肝脂肪变性。
- 免疫组化和Western blot显示美洛昔康预处理大幅增加肥胖小鼠肝细胞EGFR蛋白表达。
- 70%肝切除后,美洛昔康预处理减轻肝损伤并显著加速肥胖小鼠肝细胞有丝分裂率。
- 美洛昔康预处理组肥胖小鼠肝质量恢复加速:24小时恢复增加26%,48小时恢复增加38%。
临床怎么用
- 美洛昔康预处理可能作为改善脂肪肝切除或脂肪变性供肝移植结局的潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with fatty liver have delayed regenerative responses, increased hepatocellular injury, and increased risk for perioperative mortality. Currently, no clinical therapy exists to prevent liver failure or improve regeneration in patients with fatty liver. Previously we demonstrated that obese mice have markedly reduced levels of epidermal growth factor receptor in liver. We sought to identify pharmacologic agents to increase epidermal growth factor receptor expression to improve hepatic regeneration in the setting of fatty liver resection. METHODS: Lean (20% calories from fat) and diet-induced obese mice (60% calories from fat) were subjected to 70% or 80% hepatectomy. RESULTS: Using the BaseSpace Correlation Engine of deposited gene arrays we identified agents that increased hepatic epidermal growth factor receptor. Meloxicam was identified as inducing epidermal growth factor receptor expression across species. Meloxicam improved hepatic steatosis in diet-induced obese mice both grossly and histologically. Immunohistochemistry and Western blot analysis demonstrated that meloxicam pretreatment of diet-induced obese mice dramatically increased epidermal growth factor receptor protein expression in hepatocytes. After 70% hepatectomy, meloxicam pretreatment ameliorated liver injury and significantly accelerated mitotic rates of hepatocytes in obese mice. Recovery of liver mass was accelerated in obese mice pretreated with meloxicam (by 26% at 24 hours and 38% at 48 hours, respectively). After 80% hepatectomy, survival was dramatically increased with meloxicam treatment. CONCLUSION: Low epidermal growth factor receptor expression is a common feature of fatty liver disease. Meloxicam restores epidermal growth factor receptor expression in steatotic hepatocytes. Meloxicam pretreatment may be applied to improve outcome after fatty liver resection or transplantation with steatotic graft.
引用
- Jin X, Zimmers TA, Jiang Y, et al. Meloxicam increases epidermal growth factor receptor expression improving survival after hepatic resection in diet-induced obese mice. Surgery. 2018. PMID: 29361369. doi:10.1016/j.surg.2017.11.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。